PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Nicholas K. Mollanazar, MD, MBA - Targeting Disease Pathophysiology to Achieve Effective Treatment in Prurigo Nodularis Jun 01, 2023

Show notes

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don’t forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

Daniel S. Reich, MD, PhD - Targeting BTK: The Latest Data on the Evolving Treatment Landscape for Patients With MS Jun 01, 2023

Show notes

Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors for the treatment of MS; and Identify patients who may benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities

Linda R. Duska, MD, MPH / Debra L. Richardson, MD, FACS, FACOG - Upgrading the Treatment Algorithm for Advanced Ovarian Cancer: Expert Tips, Tools, and Patient Care Strategies for Making the Most of PARP Inhibitors Across the Disease Continuum Jun 01, 2023

Show notes

Go online to PeerView.com/UNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this discussion-based activity, two experts on ovarian cancer discuss the role of PARP inhibitors in treating advanced ovarian cancer. Upon completion of this activity, participants should be better able to: Adapt workflows to ensure that patients with ovarian cancer are receiving timely and appropriate genetic testing for BRCA, HRD, and other mutations that can help determine the role of PARP inhibitor therapy; Cite current efficacy and safety evidence on PARP inhibitors in different populations of patients with ovarian cancer; Utilize PARP inhibitors in the appropriate management of patients with ovarian cancer, including within the context of clinical trials, in accordance with current clinical evidence, guideline recommendations, mutation status, and patient needs and preferences; and Employ collaborative strategies to recognize and manage adverse events related to PARP inhibitor use in patients with ovarian cancer

Patrick A. Flume, MD / Gwen A. Huitt, MD, MS - Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management Jun 01, 2023

Show notes

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Catherine Shu, MD / Brendon M. Stiles, MD - Bringing Precision Lung Cancer Care to the Perioperative Space: How to Maximize the Impact of EGFR-Targeted Therapy in Resectable NSCLC Jun 01, 2023

Show notes

Go online to PeerView.com/PUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With adjuvant EGFR-targeted therapy now a new standard of care in resected stage I-III EGFR-mutated non-small cell lung cancer (NSCLC), what are the implications and considerations for the multidisciplinary, multimodal management of these patients? A panel of specialists in thoracic surgery and medical oncology consider this question as they discuss the importance of biomarker testing in early-stage lung cancer, the latest clinical evidence supporting the use of adjuvant EGFR-targeted therapy, and its potential expansion into the neoadjuvant setting, as well as other targeted therapies showing promise in perioperative settings. In addition, the panel demonstrates strategies for achieving better partnerships among thoracic surgeons, oncologists, pathologists, and other key specialists to facilitate predictive testing, clinical decision-making, and the optimal incorporation of EGFR-targeted therapy into treatment plans for eligible patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Select patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational, targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, Zahra Mahmoudjafari, PharmD, MBA, BCOP - Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy Jun 01, 2023

Show notes

Go online to PeerView.com/NDY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM! Upon completion of this activity, participants should be better able to: Describe the mechanisms of action, dosing, efficacy evidence, and safety evidence supporting the treatment roles of antibody-based and CAR-T therapies in multiple myeloma (MM), including CD38 and BCMA-directed agents; Implement pharmacist-guided strategies to promote optimal clinical integration of established and emerging antibody and cellular therapies across the spectrum of MM; and Develop modernized patient-, staff-, and institution-directed protocols to address practical aspects of care when using antibody and cellular therapy platforms, including dosing, safety, patient and staff counseling, and managing supportive therapies

Brenda Martone, MSN, ANP-BC, AOCNP - Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care Jun 01, 2023

Show notes

Go online to PeerView.com/VTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape for bladder cancer has rapidly evolved. The largely chemotherapy-based approaches of the past are giving way to the use of immune checkpoint inhibitors, targeted agents, and antibody–drug conjugates in advanced disease, as well as bladder-sparing and perioperative approaches in early-stage disease settings. How can oncology nurses synthesize the diverse body of clinical evidence on approved and emerging strategies into the realities of real-world cancer care to successfully address the therapeutic and educational needs of patients across the disease continuum? To help nurses rise to the challenge of modern bladder cancer management, this PeerView activity, based on a recent live event and developed in collaboration with the Bladder Cancer Advocacy Network, features an interprofessional expert panel that provides overview of the rationale and clinical evidence supporting the use of targeted, immunotherapeutic, and antibody-based strategies in bladder cancer. The panel also offers in-depth guidance on safe and effective integration of guideline-recommended therapies into personalized patient care and strategies to mitigate and manage adverse reactions and effectively support patients. Upon completion of this activity, participants should be better able to: Summarize new evidence on therapeutic strategies for bladder cancer management based on innovative drug delivery approaches, modern immunotherapy regimens, and targeted agents across the disease continuum; Develop educational strategies related to therapeutic expectations and safety considerations to enhance quality of life for patients with varying stages of bladder cancer; and Incorporate evidence- and team-based management and nursing protocols to address the unique suite of adverse events associated with approved and emerging therapeutics for bladder cancer

Stuart J. Schnitt, MD - A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment Apr 28, 2023

Show notes

Go online to PeerView.com/NRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-low breast cancer, currently defined as HER2 IHC 1+ or 2+/ISH-, accounts for approximately 50% of all breast cancers. While older HER2-targeted therapies did not show efficacy in HER2-low breast cancers, novel antibody–drug conjugates (ADCs) have demonstrated remarkable activity in this setting. Because of these advances and the FDA approval of the first HER2-targeting ADC for HER2-low breast cancer, there is an urgent need to rethink the approaches to HER2 testing so that patients with HER2-low breast cancer could be identified and get a chance to benefit from the new therapeutic approach. The understanding, definitions, and testing for HER2-low status continue to evolve, and many practical challenges and unanswered questions remain. This PeerView educational activity, based on a recent live symposium, explores the most cutting-edge information on HER2-low breast cancer, provides guidance on how to currently carry out HER2 testing to capture patients with HER2-low expression, and shares what’s on the horizon that may help further refine testing and treatment in this setting. Upon completion of this activity, participants should be better able to: Describe the spectrum of HER2 expression in breast cancer and the role of HER2-low expression as a new therapeutic target; Implement standard and emerging testing approaches to identify patients with HER2-low metastatic breast cancer to determine their eligibility for novel HER2-targeted therapies; Apply the latest evidence and guidelines to integrate HER2-targeted therapies into treatment plans for eligible patients with HER2-low metastatic breast cancer in the context of clinical practice or clinical trials; and Collaborate with the multidisciplinary team to ensure appropriate biomarker testing and optimal treatment selection for patients with HER2-low metastatic breast cancer.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Real-World Nursing Solutions for AML Care: Insights on the Effective and Safe Delivery of Innovative Therapeutics Apr 28, 2023

Show notes

Go online to PeerView.com/GFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oncology nurse professionals play a particularly important role in providing high-quality and increasingly personalized care to patients with acute myeloid leukemia (AML)—but how current are you with the “real-world” practice of nursing care in AML? Find out in this activity, featuring an oncology nurse’s expert overview of nursing principles that can be used to modernize care and optimize the use of innovative targeted therapies (such as FLT3, IDH1/2, and BCL-2 inhibitors) across the treatment continuum. Upon completion of this activity, participants should be better able to: Recognize clinical symptoms, patient-related factors, and molecular/genetic features that influence AML treatment decisions and prognosis; Summarize efficacy and safety evidence related to novel targeted and epigenetic options for the management of newly diagnosed AML, postremission disease, and the relapsed/refractory setting; Educate patients with AML about therapeutic choices with novel agent classes, treatment expectations, dosing and adherence, and safety considerations; and Manage adverse events experienced by patients with AML receiving novel targeted and epigenetic options as part of their care.

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum Apr 26, 2023

Show notes

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.